How can a hepatitis B virus carrier achieve seroclearance?

Dec 29, 2022 Source: Cainiu Health

Dr. Jin Zhongkui

Introduction

It is relatively simple for hepatitis B virus carriers to become negative, but it is more difficult for hepatitis B surface antigen to turn negative. The treatment of hepatitis B virus carriers requires individualized therapy. If antiviral treatment is conducted according to the indications for antiviral therapy, achieving viral negativity is relatively easy. During the antiviral treatment process, or when selecting a treatment regimen, interferon-based antiviral therapy may be considered.

In real life, a large portion of the population are carriers of the hepatitis B virus. This condition is somewhat contagious. How can hepatitis B virus carriers achieve a negative status?

How Can Hepatitis B Carriers Achieve a Negative Status?

For individuals carrying the hepatitis B virus, achieving an overall negative viral status is relatively straightforward, but turning negative for hepatitis B surface antigen (HBsAg) is more difficult. Treatment for hepatitis B carriers should be individualized. If antiviral therapy is administered according to the appropriate indications, it is often possible to achieve viral negativity. During antiviral treatment, or when selecting a treatment regimen, interferon-based antiviral therapy may be considered if the patient meets the criteria. Interferon therapy offers a higher probability of achieving HBsAg seroclearance. Patients with low levels of HBV surface antigen have a greater chance of achieving HBsAg negativity.

Hepatitis B carriers may have no clinical symptoms or manifestations and may feel no discomfort, appearing no different from healthy individuals. However, when the virus damages the liver, certain clinical symptoms may appear, such as fatigue, loss of appetite, reduced physical strength, dry throat, bitter taste in the mouth, frequent dreaming, and pain under the ribs.

Drinking alcohol, emotional stress, or excessive fatigue can worsen the condition, leading in severe cases to nausea, vomiting, and jaundice. The disease may progress to cirrhosis. When cirrhosis develops, symptoms such as fatigue, edema, ascites, and abdominal distension may occur, and even gastrointestinal bleeding such as hematemesis or melena may appear. We hope this answer has been helpful to you. Wishing you good health and a happy life!

View All

Can short-acting interferon be used again after having been administered for 4 years and then discontinued for 4 years?

If the underlying disease (e.g., chronic hepatitis B or C) is currently in an active phase, with abnormal liver function or elevated viral load, and no severe baseline conditions (e.g., cirrhosis) have occurred during the 4-year period off treatment, the patient may be eligible for re-treatment—provided a physician evaluates them as having good overall tolerance and no contraindications to interferon use (such as severe cardiac or renal disease, or psychiatric history). An individualized dosing regimen would then be required.